| Literature DB >> 35620520 |
Marieke Nederend1,2, Monique R M Jongbloed1,2,3, Philippine Kiès1,2, Hubert W Vliegen1,2, Berto J Bouma4, Madelien V Regeer1,2, Dave R Koolbergen1,4,5,6, Mark G Hazekamp1,4,5,6, Martin J Schalij1,2, Anastasia D Egorova1,2.
Abstract
Background: Patients with transposition of the great arteries (TGA) after an atrial switch or congenitally corrected TGA (ccTGA) are prone to systemic right ventricular (sRV) failure. Tricuspid valve (TV) regurgitation aggravates sRV dysfunction. Timely TV surgery stabilizes sRV function, yet the development of atrioventricular (AV)-conduction disturbances in the course of sRV failure can contribute to sRV dysfunction through pacing-induced dyssynchrony. This study aims to explore the incidence, timing, and functional consequences of AV-block requiring ventricular pacing after TV surgery in patients with sRV.Entities:
Keywords: cardiac resynchronization therapy; congenital heart disease; heart failure; pacemaker; systemic right ventricle; transposition of the great arteries (TGA); tricuspid valve surgery
Year: 2022 PMID: 35620520 PMCID: PMC9127255 DOI: 10.3389/fcvm.2022.870459
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Figure 1The 12-lead ECG recordings and chest X-rays of a patient with congenitally corrected transposition of the great arteries, illustrating the effects of subpulmonary ventricular pacing, and cardiac resynchronization therapy on an electrocardiogram (ECG). The 12-lead ECG with (A) sinus rhythm and a total atrioventricular (AV)-block with ventricular/junctional escape rate of 48/min; (B) sequential subpulmonary left ventricular pacing of 75/min, note the broad paced QRS complex of 245 ms; (C) biventricular pacing after upgrade to a cardiac resynchronization therapy (CRT), note the reduction of QRS duration to 137 ms, illustrative of the electrical contribution of the systemic right ventricular (sRV) activation. (D) Postero-anterior, (E) lateral chest X-ray showing the pacing lead in the coronary sinus (red arrow) in the systemic right ventricle (red), atrial lead in the right atrium (yellow arrow), and transvenous pacing and ICD leads (blue arrow) in the subpulmonary left ventricle (LV) (blue), note the mechanical tricuspid valve in situ (orange).
Figure 2Overview of the study population and the follow-up. sRV, systemic right ventricle; TV, tricuspid valve; CRT, cardiac resynchronization therapy; AV, atrioventricular; LV, subpulmonary left ventricle.
Patient characteristics at baseline and patient characteristics compared between the group that retains native atrioventricular (AV)-conduction and the group that develops high-degree AV-block.
|
|
|
|
|
|
|---|---|---|---|---|
| Age at surgery (years) | 38 ± 13 | 40.5 ± 12.1 | 38.2 ± 13.1 | 0.643 |
| Female | 15 (54%) | 6 (46%) | 6 (50%) | 0.848 |
| Anatomy | 0.821 | |||
| TGA with atrial switch procedure | 12 (43%) | 6 (46%) | 5 (42%) | |
| ccTGA | 16 (57%) | 7 (54%) | 7 (58%) | |
| NYHA functional class | 0.429 | |||
| NYHA I-II | 10 (36%) | 5 (38%) | 5 (42%) | |
| NYHA III-IV | 15 (54%) | 8 (62%) | 4 (33%) | |
| Unknown | 3 (11%) | 0 (0%) | 3 (25%) | |
|
| ||||
| Rhythm | 0.183 | |||
| Sinus rhythm | 16 (57%) | 9 (69%) | 5 (42%) | |
| Atrial fibrillation or flutter | 5 (18%) | 2 (15%) | 2 (17%) | |
| Atrial rhythm | 1 (4%) | 0 (0%) | 1 (8%) | |
| Atrial pacing | 3 (11%) | 1 (8%) | 2 (17%) | |
| PR duration (msec) | 189 ± 43 | 192 ± 24 | 196 ± 53 | 0.838 |
| QRS duration (msec) | 140 ± 35 | 134 ± 34 | 144 ± 35 | 0.523 |
|
| ||||
| Beta blocker | 9 (32%) | 5 (39%) | 4 (33%) | 0.779 |
| ACE-i/ARB/ARNI | 19 (68%) | 11 (85%) | 7 (58%) | 0.683 |
| MRA | 3 (11%) | 2 (15%) | 1 (8%) | 0.774 |
| Diuretics (loop and thiazide) | 12 (43%) | 6 (46%) | 6 (50%) | 0.342 |
| None | 4 (14%) | 1 (8%) | 1 (8%) | 0.784 |
|
| ||||
| Qualitative sRV function | 0.051 | |||
| Normal | 2 (7%) | 0 (0%) | 1 (8%) | |
| Mildly reduced | 9 (32%) | 2 (15%) | 7 (58%) | |
| Moderately reduced | 14 (50%) | 9 (69%) | 3 (25%) | |
| Severely reduced | 1 (4%) | 1 (8%) | 0 (0%) | |
| Unknown | 2 (7%) | 1 (8%) | 1 (8%) | |
| Tricuspid regurgitation | 0.361 | |||
| Grade II | 1 (4%) | 0 (0%) | 1 (8%) | |
| Grade III | 15 (54%) | 6 (46%) | 7 (58%) | |
| Grade IV | 10 (36%) | 6 (46%) | 3 (25%) | |
| Unknown | 2 (7%) | 1 (8%) | 1 (8%) | |
|
| ||||
| Type of tricuspid valve intervention | 0.198 | |||
| TVR | 17 (61%) | 8 (62%) | 7 (58%) | |
| Biological valve | 5 (29%) | 4 (50%) | 1 (14%) | |
| Mechanical valve | 12 (71%) | 4 (50%) | 6 (86%) | |
| TVP | 11 (39%) | 5 (38%) | 5 (42%) | |
| Concomitant procedures | 19 (68%) | 9 (69%) | 8 (67%) | 0.891 |
| AP banding | 2 (7%) | 0 (0%) | 2 (17%) | 0.125 |
| Baffle leak closure | 4 (14%) | 2 (15%) | 1 (8%) | 0.588 |
| Baffle/conduit replacement or dilatation plasty | 7 (25%) | 3 (23%) | 4 (33%) | 0.568 |
| MV annuloplasty | 6 (21%) | 3 (23%) | 2 (17%) | 0.689 |
| VSD closure | 1 (4%) | 0 (0%) | 1 (8%) | 0.288 |
| CABG | 1 (4%) | 1 (8%) | 0 (0%) | 0.327 |
Data are expressed as n (%) unless otherwise indicated.
SD, standard deviation; TGA, transposition of the great arteries; ccTGA, congenitally corrected TGA; NYHA, New York Heart Association; ECG, electrocardiogram; Q, quartile; P/PM, pacemaker; CRT, cardiac resynchronization therapy; ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, Mineralocorticoid receptor antagonists; sRV, systemic right ventricle; TVR, tricuspid valve replacement; TVP, tricuspid valve annuloplasty; AP, arteria pulmonalis; MV, mitral valve; VSD, ventricular septum defect; CABG, coronary artery bypass graft surgery.
Figure 3Cumulative incidence curve for chronic LV pacing after TV surgery.
Clinical outcomes at last follow-up, patients with cardiac resynchronization therapy before and concomitant TV surgery were excluded from analysis (n = 2).
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| NYHA functional class | 0.062 | |||
| NYHA I-II | 13 (52%) | 9 (69%) | 4 (33%) | |
| NYHA III-IV | 10 (40%) | 3 (23%) | 7 (58%) | |
| Unknown | 2 (8%) | 1 (8%) | 1 (8%) | |
| QRS duration (msec) | 162 ± 56 | 116 ± 23 | 217 ± 24 | <0.001 |
| mean ± SD | ||||
|
| ||||
| Beta blocker | 8 (32%) | 3 (23%) | 5 (42%) | 0.304 |
| ACE-i/ARB/ARNI | 19 (76%) | 10 (77%) | 9 (75%) | 0.924 |
| MRA | 12 (48%) | 5 (39%) | 7 (58%) | 0.292 |
| Diuretics (loop or thiazide) | 13 (52%) | 5 (39%) | 8 (67%) | 0.133 |
|
| ||||
| eGFR (ml/min/1.73m2) | 67.5 ± 16.2 | 70.5 ± 15.6 | 64.2 ± 17.1 | 0.394 |
| mean ± SD | ||||
| NT-pro-BNP (ng/l) | 846.5 [485.3 – 3332.5] | 495.0 [355.0– 690.0] | 2746.0 [1242.0 – 6879.0] | 0.004 |
| Median [Q1-Q3] | ||||
|
| ||||
| Qualitative sRV function | 0.186 | |||
| Mildly reduced | 3 (12%) | 3 (23%) | 0 (0%) | |
| Moderately reduced | 10 (44%) | 5 (39%) | 5 (42%) | |
| Severely reduced | 10 (44%) | 4 (31%) | 6 (50%) | 0.263 |
| Missing | 2 (8%) | 1 (8%) | 1 (8%) | |
| At least one echocardiographic class of deterioration of sRV function | 13 (52%) | 3 (27%) | 10 (83%) | 0.001 |
| Tricuspid regurgitation | 0.816 | |||
| Grade I or less | 16 (64%) | 9 (69%) | 7 (58%) | |
| Grade II | 5 (20%) | 2 (15%) | 3 (25%) | |
| Grade III | 2 (8%) | 1 (8%) | 1 (8%) | |
| Missing | 2 (8%) | 1 (8%) | 1 (8%) | |
|
| ||||
| Composite endpoint | 13 (52%) | 4 (31%) | 9 (75%) | 0.027 |
| CRT | 5 (20%) | 1 (7%) | 4 (33%) | |
| VAD | 3 (12%) | 2 (15%) | 1 (8%) | |
| Death | 7 (28%) | 1 (7%) | 6 (50%) |
Data are expressed as n (%) unless stated otherwise.
Is statistically significant.
CRT, cardiac resynchronization therapy; VAD, ventricular assist device; ECG, electrocardiogram; NYHA, New York Heart Association; sRV, systemic right ventricle; eGFR, estimated glomerular filtration rate; NT-pro-BNP, N-terminal-pro hormone B-type natriuretic peptide; SD, standard deviation; Q, quartile; ACE-i, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor-neprilysin inhibitor; MRA, mineralocorticoid receptor antagonists.
Figure 4(A) Percentage of patients having reached the composite endpoint of mortality, ventricular assist device (VAD) implantation, or upgrade to cardiac resynchronization therapy (CRT) due to progressive heart failure, (B) QRS duration (ms), (C) N-terminal-pro hormone B-type natriuretic peptide (NT-pro-BNP, ng/L), and (D) the percentage of patients with at least one echocardiographic class of deterioration of sRV function at last follow up after TV surgery in patients with native AV-conduction (blue) vs. chronic left ventricular pacing (red). The * symbol indicates statistically significant values.